Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCYRN1 siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
BCYRN1 siRNA is a research-use small interfering RNA (an RNA-interference oligonucleotide) designed to target and knock down the expression of brain cytoplasmic RNA 1 (BCYRN1), a long non-coding RNA (lncRNA) that is upregulated in several cancers, including prostate cancer, cervical cancer, gastric carcinoma, glioma, and renal cell carcinoma. In preclinical in vitro and in vivo studies, transfection of BCYRN1 siRNA has been shown to suppress cell proliferation, migration, and invasion, while promoting apoptosis. It is primarily used as a laboratory tool for gene knockdown and has not been developed as a clinical therapeutic.
- Other names
- BCYRN1-siRNABCYRN-1-siRNABCYRN 1-siRNAsi-BCYRN1si-BCYRN-1si-BCYRN 1
Beyond the preview
Go deeper on BCYRN1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCYRN1 siRNA.